Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria

• •Histologically confirmed supratentorial grade IV astrocytoma
• •* Glioblastoma multiforme
• •Subtotal resection or biopsy with measurable and contrast-enhancing disease on the postoperative, pretreatment MRI/CT scan
• •Performance status - Karnofsky 60-100%
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Hemoglobin at least 9.0 g/dL
• •Bilirubin normal
• •Creatinine normal
• •Creatinine clearance at least 60 mL/min
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No serious concurrent infection or medical illness that would jeopardize ability to receive protocol chemotherapy with reasonable safety
• •No other prior malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer
• •No grade 2 or greater pre-existing sensory neuropathy
• •No history of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol chemotherapy
• •Mini mental score at least 15
• •No prior immunotherapy for glioblastoma multiforme
• •No prior biologic therapy for glioblastoma multiforme, including:
• •* Immunotoxins
• •* Immunoconjugates
• •* Antiangiogenesis compounds
• •* Antisense
• •* Peptide receptor antagonists
• •* Interferons
• •* Interleukins
• •* Tumor infiltrating lymphocytes
• •* Lymphokine activated killer cells
• •* Gene therapy
• •No concurrent filgrastim (G-CSF)
• •No prior chemotherapy for glioblastoma multiforme
• •No prior hormonal therapy for glioblastoma multiforme
• •Prior glucocorticoid therapy for glioblastoma multiforme allowed
• •Must be maintained on a stable (lowest required dose) corticosteroid regimen for at least 5 days before and during study
• •No concurrent dexamethasone as an antiemetic
• •No prior radiotherapy for glioblastoma multiforme
• •Recovered from immediate postoperative period
• •At least 10 days since prior anticonvulsant drug that induces hepatic metabolic enzymes
• •No other concurrent investigational agents